EDX Medical Group (LSE:EDX), a Cambridge-based diagnostics company, has issued a steady flow of announcements in recent months. In mid-September 2026 it said it had signed a three-year employee health screening agreement with Arnold Clark Group, the UK car dealership group. That followed a £2.7 million share fundraise in August. On 1 October the company also said it would give an online investor presentation.

What the Company Does

EDX Medical develops and supplies digital diagnostic products and services aimed at the earlier detection and treatment of major diseases. It was founded by Professor Sir Christopher Evans and is led by chief executive Dr Mike Hudson. The group runs its own facilities in Cambridge and Oxford and has a strategic Partnership with Thermo Fisher. Its recent activity covers employer health screening, cancer testing services and a rapid pneumonia test. The company said in August that the pneumonia test was being used for NHS patients.

The Arnold Clark Contract

The agreement announced on 17 September 2026 covers EDX's health and wellbeing screening programme for Arnold Clark staff. Arnold Clark employs about 11,600 people at around 200 UK locations. EDX said it expects the contract to bring in annual Revenue of £1.4 million to £1.6 million. Participation is voluntary. Blood samples are taken at sessions held on Arnold Clark premises from October 2026, and the results are combined with health and family history questionnaires. The company said its biomarker panels cover more than 220 disease conditions, including early signs of cancer and cardiovascular disease. It added that it is in talks with other large UK employers.

Prostate Testing and Other Developments

EDX is the lead delivery partner for a not-for-profit Scottish Prostate Cancer Initiative, which aims to test 25,000 men. In an update on 27 August 2026, the company said more than 12,500 men were tested between late March and June. A second phase, covering another 12,500 men over 31 sessions, runs until November. EDX supplies the PSA tests, runs the events, analyses samples in its laboratory and adds blood samples to its biobank for research. In July the company also announced the full launch of its BC95 bowel cancer testing service and a service agreement with Astron Health.

Financial Picture

The August fundraise was a subscription for 19,378,563 new shares at 14p each, raising about £2.7 million. Each new share came with warrants over two further shares. The proceeds are earmarked for expanding the employee screening service, and the company had 431,373,146 shares in issue after the issue. EDX also said the board had deferred £860,000 of revenue, previously expected in the year to 31 March 2026, into the current financial year after discussions with auditors. EDX has not reported a dividend.

Sector and index Context

EDX is one of the smaller healthcare companies on the FTSE AIM All Share Index. Like many early-stage diagnostics groups, it relies on share funding while it builds recurring revenue.

Key Risks

The company is at an early commercial stage. Reported revenue has been modest and has been affected by timing, as the revenue deferral shows. Further fundraises could dilute existing holders, and warrants attached to the August subscription could add to the share count in time. Expected contract revenues depend on how many employees choose to take part.

What to Watch Next

Investors will be watching for definitive contracts with the three large UK employers that agreed in principle in July. EDX said testing for them was still expected to start in the fourth quarter of 2026. Revenue from the Arnold Clark sessions, final results from the Scottish prostate programme and interim results for the half to 30 September are the other milestones to follow.